BBOT (BridgeBio Oncology Therapeutics) Total Inventories: $0.00 Mil (As of Mar. 2026)


BBOT BridgeBio Oncology Therapeutics Inc BBOT
12 GF Score
Price $8.40
View Full Analysis

What is BridgeBio Oncology Therapeutics Total Inventories?

BridgeBio Oncology Therapeutics BBOT +3.70% 12 Total Inventories is $0.00 Mil as of Mar. 2026. GuruFocus rates BBOT with a GF Score™ of 12/100.

BridgeBio Oncology Therapeutics's total inventories for the quarter that ended in Mar. 2026 was $0.00 Mil. BridgeBio Oncology Therapeutics's average total inventories from the quarter that ended in Dec. 2025 to the quarter that ended in Mar. 2026 was $0.00 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. BridgeBio Oncology Therapeutics's Net-Net Working Capital per share for the quarter that ended in Mar. 2026 was $2.58.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

BridgeBio Oncology Therapeutics  (NAS:BBOT) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

BridgeBio Oncology Therapeutics's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2026 is

Net-Net Working Capital Per Share (Q: Mar. 2026 )
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(252.275+0.75 * 0+0.5 * 0-45.366
-0-0)/80.089
=2.58

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

BridgeBio Oncology Therapeutics's Days Inventory for the three months ended in Mar. 2026 is calculated as:

Days Inventory=Average Total Inventories (Q: Mar. 2026 )/Cost of Goods Sold (Q: Mar. 2026 )*Days in Period
=0/0*365 / 4
=

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

BridgeBio Oncology Therapeutics's Inventory Turnover for the quarter that ended in Mar. 2026 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Mar. 2026 ) / Average Total Inventories (Q: Mar. 2026 )
=0 / 0
=N/A

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

BridgeBio Oncology Therapeutics's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Mar. 2026 ) / Revenue (Q: Mar. 2026 )
=0 / 0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

BridgeBio Oncology Therapeutics Total Inventories Related Terms

BridgeBio Oncology Therapeutics Total Inventories Historical Data

* Premium members only.

The historical data trend for BridgeBio Oncology Therapeutics's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BridgeBio Oncology Therapeutics Total Inventories Chart

BridgeBio Oncology Therapeutics Annual Data
Trend Dec23 Dec24 Dec25
Total Inventories
0.00 0.00 0.00

BridgeBio Oncology Therapeutics Quarterly Data
Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Inventories Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
BBOT
12GF Score
BridgeBio Oncology Therapeutics Inc BBOT
Total Inventories is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BridgeBio Oncology Therapeutics Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Frequently Asked Questions Learn more about Total Inventories →
What does a Total Inventories of $0.00 Mil mean?
BridgeBio Oncology Therapeutics (BBOT) has a Total Inventories of $0.00 Mil as of Mar. 2026. The total amount of inventory as recorded on a company's balance sheet. View historical data for BridgeBio Oncology Therapeutics and its competitors.
Is BridgeBio Oncology Therapeutics' Total Inventories too high?
BridgeBio Oncology Therapeutics' current Total Inventories is $0.00 Mil. Overall, BridgeBio Oncology Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does BridgeBio Oncology Therapeutics' Total Inventories compare to FTH and MNPR?
BridgeBio Oncology Therapeutics' Total Inventories of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Biotechnology company?
A good Total Inventories depends on the Biotechnology industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for BridgeBio Oncology Therapeutics and its competitors. BridgeBio Oncology Therapeutics's current Total Inventories is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BridgeBio Oncology Therapeutics stock overvalued right now?
BridgeBio Oncology Therapeutics (BBOT) has a current Total Inventories of $0.00 Mil. The current Total Inventories is $0.00 Mil. BridgeBio Oncology Therapeutics' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For BridgeBio Oncology Therapeutics (BBOT), the current Total Inventories is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BridgeBio Oncology Therapeutics Business Description

Address 256 East Grand Avenue, Suite 104, South San Francisco, CA, USA, 94080
BridgeBio Oncology Therapeutics Inc, is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes. The Company operates in one operating and reportable segment within the United States, developing oncology therapies through various related development projects.
12GF Score

Get the complete analysis for BBOT

Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.40
Price